OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women

Completed · Phase 4

Conditions studied: Osteoporosis, Postmenopausal

In brief

To determine how prior therapy with alendronate or risedronate in postmenopausal women with osteoporosis influences the clinical effectiveness of teriparatide; The primary objective of the study is to compare the teriparatide (human, recombinant PTH\[1-34\])-associated change from baseline in a marker of bone formation, N-terminal propeptide of type I collagen (P1NP), between subjects previously treated with risedronate and those previously treated with alendronate.

Key facts

Study ID

NCT00130403

Run by

Sanofi

People needed

290

Starts

2004-03-01

Expected to finish

2007-03-01

Last updated by the study team

2011-01-11

Who can join

Age: 55 and older, up to 85. Sex: female. Healthy volunteers: not accepted.

Where it is running

• sanofi-aventis, US — Bridgewater, New Jersey, United States
• sanofi-aventis, Australia — Cove, New South Wales, Australia
• sanofi-aventis, Belgium — Diegem, Belgium
• sanofi-aventis, Canada — Laval, Quebec, Canada
• sanofi-aventis, France — Paris, France
• sanofi-aventis, Netherlands — Gouda, Netherlands
• sanofi-aventi, UK — Guildford, Surrey, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.